CD274 and neoplasm: In particular, 53L10 tribody targeting PD-L1 displayed much more potent effects than the combination of 53 P with all the clinically validated mAbs and led to complete tumor regression in vivo, showing much higher efficacy than the combination of 53 P and atezolizumab.